Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly trabectedin combined with Metronomic Cyclophosphamide in Patients with Advanced Pretreated Soft-tissue Sarcomas. A Phase I/II study from the French Sarcoma Group.

Trial Profile

Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly trabectedin combined with Metronomic Cyclophosphamide in Patients with Advanced Pretreated Soft-tissue Sarcomas. A Phase I/II study from the French Sarcoma Group.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 Jun 2016

At a glance

  • Drugs Trabectedin (Primary) ; Cyclophosphamide
  • Indications Soft tissue sarcoma
  • Focus Adverse reactions
  • Acronyms TARMIC
  • Most Recent Events

    • 15 Jun 2016 Planned End Date changed from 19 Oct 2018 to 1 Dec 2018.
    • 15 Jun 2016 Planned primary completion date changed to 1 Jun 2018.
    • 15 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top